Anteris Strengthens Board with Medical Device and Governance Experts
Event summary
- Anteris appointed Susan Knight and Stephen Denaro to its Board of Directors on May 13, 2026.
- Susan Knight, former Board Chair of Surmodics, will serve on the Audit and Risk Committee.
- Stephen Denaro rejoins the Board with deep knowledge of Anteris' strategic priorities.
- Appointments aim to strengthen governance as Anteris advances its DurAVR® global pivotal trial.
The big picture
Anteris is bolstering its governance capabilities amid critical clinical and commercial milestones for its DurAVR® THV. The appointments of Susan Knight and Stephen Denaro reflect a strategic focus on audit oversight and industry expertise as the company navigates regulatory pathways for its biomimetic valve technology. This move aligns with broader trends in medical device companies strengthening boards to support complex product launches and global expansion.
What we're watching
- Governance Dynamics
- How Susan Knight's audit committee experience will influence Anteris' risk management strategies.
- Regulatory Milestones
- The pace at which Anteris advances the DurAVR® THV towards U.S. and EMA licensure.
- Strategic Execution
- Whether the new board members can accelerate Anteris' global commercial objectives.
Related topics